S&P Futures
4,212.75 +2.75 (+0.07%) Dow Futures
33,299.00 +39.00 (+0.12%) Nasdaq Futures
13,401.00 +9.00 (+0.07%) Russell 2000 Futures
1,970.80 +1.30 (+0.07%) Crude Oil
91.52 -0.41 (-0.45%) Gold
1,807.10 -6.60 (-0.36%)
Adial Pharmaceuticals, Inc. (ADIL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.5886 |
| Open | 0.5900 |
| Bid | 0.5800 x 1300 |
| Ask | 0.6300 x 800 |
| Day's Range | 0.5520 - 0.6119 |
| 52 Week Range | 0.4500 - 5.0800 |
| Volume | |
| Avg. Volume | 732,085 |
| Market Cap | 15.082M |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8580 |
| Earnings Date | May 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ADIL
Related Research
- Adial Pharmaceuticals, IncAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.RatingFair ValueEconomic Moat7 months agoMorningstar
- GlobeNewswire
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call
- Benzinga
EXCLUSIVE: Adial Pharma's AD04 Effective In Heavy Drinker Alcohol Use Disorder Patients
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo. Trial Results: AD04 achieved a statistically significant mean reduction compared to placebo from baseline at month six in heavy drinking days among "heavy drinkers" (average <10 drinks per drinking day), accounting for around two-thirds of the trial population. A similar trend was seen in the combine
- GlobeNewswire
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ETCHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plan
